Login to Your Account

Mipomersen NDA Coming Soon

Isis Gets $29M Cash Boost in Biogen SMA Option Deal

By Jennifer Boggs
Managing Editor

Thursday, January 5, 2012
As investors await a mipomersen filing later this quarter, Isis Pharmaceuticals Inc. padded its cash position with an early stage option deal for one of its rare disease antisense programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription